首页 > 最新文献

New England Journal of Medicine最新文献

英文 中文
SENIOR-RITA - Is It All about Angiography? SENIOR-RITA - 一切都与血管造影有关吗?
IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-07 DOI: 10.1056/NEJMe2411477
Simone Biscaglia
{"title":"SENIOR-RITA - Is It All about Angiography?","authors":"Simone Biscaglia","doi":"10.1056/NEJMe2411477","DOIUrl":"https://doi.org/10.1056/NEJMe2411477","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frailty in Older Adults. 老年人的虚弱。
IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-07 DOI: 10.1056/NEJMc2411327
Bruce Leff, Christine Ritchie, Katherine A Ornstein
{"title":"Frailty in Older Adults.","authors":"Bruce Leff, Christine Ritchie, Katherine A Ornstein","doi":"10.1056/NEJMc2411327","DOIUrl":"10.1056/NEJMc2411327","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Audio Interview: The Marburg Virus Outbreak in Rwanda. 音频访谈:卢旺达爆发的马尔堡病毒
IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-07 DOI: 10.1056/NEJMe2413925
Eric J Rubin, Lindsey R Baden, Sabin Nsanzimana, Stephen Morrissey
{"title":"Audio Interview: The Marburg Virus Outbreak in Rwanda.","authors":"Eric J Rubin, Lindsey R Baden, Sabin Nsanzimana, Stephen Morrissey","doi":"10.1056/NEJMe2413925","DOIUrl":"https://doi.org/10.1056/NEJMe2413925","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidural Glucocorticoid Injection for Lumbosacral Radicular Pain. 硬膜外注射糖皮质激素治疗腰骶部疼痛
IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-07 DOI: 10.1056/NEJMvcm2313448
David Hao, R Jason Yong, Samer Narouze, Alexandra E Fogarty, Olivia M Sutton, Milan P Stojanovic
{"title":"Epidural Glucocorticoid Injection for Lumbosacral Radicular Pain.","authors":"David Hao, R Jason Yong, Samer Narouze, Alexandra E Fogarty, Olivia M Sutton, Milan P Stojanovic","doi":"10.1056/NEJMvcm2313448","DOIUrl":"https://doi.org/10.1056/NEJMvcm2313448","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simple Strategies to Reduce Cardiac Strain in Older Adults in Extreme Heat. 减少老年人在酷暑中心脏负荷的简单策略。
IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-07 DOI: 10.1056/NEJMc2407812
Georgia K Chaseling, Nicole T Vargas, Lily Hospers, Hadiatou Barry, Amy Harwood, Connor Graham, Audrey-Ann Bartlett, Amélie Debray, Grant Lynch, Anthony Capon, Craig G Crandall, Maria Fiatarone Singh, Yorgi Mavros, Peng Bi, Anil Nigam, Malorie Chabot-Blanchet, Daniel Gagnon, Ollie Jay
{"title":"Simple Strategies to Reduce Cardiac Strain in Older Adults in Extreme Heat.","authors":"Georgia K Chaseling, Nicole T Vargas, Lily Hospers, Hadiatou Barry, Amy Harwood, Connor Graham, Audrey-Ann Bartlett, Amélie Debray, Grant Lynch, Anthony Capon, Craig G Crandall, Maria Fiatarone Singh, Yorgi Mavros, Peng Bi, Anil Nigam, Malorie Chabot-Blanchet, Daniel Gagnon, Ollie Jay","doi":"10.1056/NEJMc2407812","DOIUrl":"https://doi.org/10.1056/NEJMc2407812","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screened Out - How a Survey Change Sheds Light on Iatrogenic Opioid Use Disorder. 被筛查出来--调查的变化如何揭示了阿片类药物使用障碍的诱因。
IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-06 DOI: 10.1056/NEJMp2410911
Andrew Kolodny, Robert M Bohler
{"title":"Screened Out - How a Survey Change Sheds Light on Iatrogenic Opioid Use Disorder.","authors":"Andrew Kolodny, Robert M Bohler","doi":"10.1056/NEJMp2410911","DOIUrl":"https://doi.org/10.1056/NEJMp2410911","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
I Am Nothing 我什么都不是
IF 158.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-02 DOI: 10.1056/nejmp2405897
Hemal N. SampatFrom the Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston.
When an older patient hears that his physician is of Indian descent, the two find an immediate, resonant connection in a haunting song recalled from long ago and far away.
当一位年长的病人听说他的医生是印第安人后裔时,两人在一首萦绕在耳边的歌声中找到了一种直接而共鸣的联系。
{"title":"I Am Nothing","authors":"Hemal N. SampatFrom the Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston.","doi":"10.1056/nejmp2405897","DOIUrl":"https://doi.org/10.1056/nejmp2405897","url":null,"abstract":"When an older patient hears that his physician is of Indian descent, the two find an immediate, resonant connection in a haunting song recalled from long ago and far away.","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":158.5,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erysipelas. 红皮病
IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-31 DOI: 10.1056/NEJMicm2404869
Nathan I Wood, Andre N Sofair
{"title":"Erysipelas.","authors":"Nathan I Wood, Andre N Sofair","doi":"10.1056/NEJMicm2404869","DOIUrl":"https://doi.org/10.1056/NEJMicm2404869","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. 基于 Inavolisib 的 PIK3CA 突变晚期乳腺癌疗法
IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-31 DOI: 10.1056/NEJMoa2404625
Nicholas C Turner, Seock-Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, Noopur Shankar, Guiyuan Lei, Thomas J Stout, Katherine E Hutchinson, Jennifer L Schutzman, Chunyan Song, Komal L Jhaveri

Background: Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) that also promotes the degradation of mutated p110α. Inavolisib plus palbociclib-fulvestrant has shown synergistic activity in preclinical models and promising antitumor activity in early-phase trials.

Methods: In a phase 3, double-blind, randomized trial, we compared first-line inavolisib (at an oral dose of 9 mg once daily) plus palbociclib-fulvestrant (inavolisib group) with placebo plus palbociclib-fulvestrant (placebo group) in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who had had relapse during or within 12 months after the completion of adjuvant endocrine therapy. The primary end point was progression-free survival as assessed by the investigator.

Results: A total of 161 patients were assigned to the inavolisib group and 164 to the placebo group; the median follow-up was 21.3 months and 21.5 months, respectively. The median progression-free survival was 15.0 months (95% confidence interval [CI], 11.3 to 20.5) in the inavolisib group and 7.3 months (95% CI, 5.6 to 9.3) in the placebo group (hazard ratio for disease progression or death, 0.43; 95% CI, 0.32 to 0.59; P<0.001). An objective response occurred in 58.4% of the patients in the inavolisib group and in 25.0% of those in the placebo group. The incidence of grade 3 or 4 neutropenia was 80.2% in the inavolisib group and 78.4% in the placebo group; grade 3 or 4 hyperglycemia, 5.6% and 0%, respectively; grade 3 or 4 stomatitis or mucosal inflammation, 5.6% and 0%; and grade 3 or 4 diarrhea, 3.7% and 0%. No grade 3 or 4 rash was observed. Discontinuation of any trial agent because of adverse events occurred in 6.8% of the patients in the inavolisib group and in 0.6% of those in the placebo group.

Conclusions: In patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, inavolisib plus palbociclib-fulvestrant led to significantly longer progression-free survival than placebo plus palbociclib-fulvestrant, with a greater incidence of toxic effects. The percentage of patients who discontinued any trial agent because of adverse events was low. (Funded by F. Hoffmann-La Roche; INAVO120 ClinicalTrials.gov number, NCT04191499.).

背景Inavolisib是磷脂酰肌醇3-激酶复合物(由PIK3CA编码)p110催化亚基α异构体的高效选择性抑制剂,它还能促进突变p110α的降解。Inavolisib 加 palbociclib-fulvestrant 已在临床前模型中显示出协同活性,并在早期试验中显示出良好的抗肿瘤活性:在一项3期双盲随机试验中,我们比较了一线inavolisib(口服剂量为9毫克,每天一次)加palbociclib-fulvestrant(inavolisib组)和安慰剂加palbociclib-fulvestrant(安慰剂组)治疗PIK3CA突变、激素受体阳性的白血病患者、激素受体阳性、人表皮生长因子受体 2 (HER2) 阴性的局部晚期或转移性乳腺癌患者,且在辅助内分泌治疗期间或治疗结束后 12 个月内复发者。主要终点是由研究者评估的无进展生存期:共有161名患者被分配到依那韦利昔组,164名患者被分配到安慰剂组;中位随访时间分别为21.3个月和21.5个月。inavolisib组的中位无进展生存期为15.0个月(95%置信区间[CI]为11.3至20.5),安慰剂组为7.3个月(95%置信区间[CI]为5.6至9.3)(疾病进展或死亡的危险比为0.43;95%置信区间[CI]为0.32至0.59;PConclusions:在PIK3CA突变、激素受体阳性、HER2阴性的局部晚期或转移性乳腺癌患者中,inavolisib联合palbociclib-fulvestrant的无进展生存期明显长于安慰剂联合palbociclib-fulvestrant,但毒性反应发生率更高。因不良反应而停用任何试验药物的患者比例较低。(由 F. Hoffmann-La Roche 公司资助;INAVO120 临床试验项目编号:NCT04191499)。
{"title":"Inavolisib-Based Therapy in <i>PIK3CA</i>-Mutated Advanced Breast Cancer.","authors":"Nicholas C Turner, Seock-Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, Noopur Shankar, Guiyuan Lei, Thomas J Stout, Katherine E Hutchinson, Jennifer L Schutzman, Chunyan Song, Komal L Jhaveri","doi":"10.1056/NEJMoa2404625","DOIUrl":"https://doi.org/10.1056/NEJMoa2404625","url":null,"abstract":"<p><strong>Background: </strong>Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by <i>PIK3CA</i>) that also promotes the degradation of mutated p110α. Inavolisib plus palbociclib-fulvestrant has shown synergistic activity in preclinical models and promising antitumor activity in early-phase trials.</p><p><strong>Methods: </strong>In a phase 3, double-blind, randomized trial, we compared first-line inavolisib (at an oral dose of 9 mg once daily) plus palbociclib-fulvestrant (inavolisib group) with placebo plus palbociclib-fulvestrant (placebo group) in patients with <i>PIK3CA</i>-mutated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who had had relapse during or within 12 months after the completion of adjuvant endocrine therapy. The primary end point was progression-free survival as assessed by the investigator.</p><p><strong>Results: </strong>A total of 161 patients were assigned to the inavolisib group and 164 to the placebo group; the median follow-up was 21.3 months and 21.5 months, respectively. The median progression-free survival was 15.0 months (95% confidence interval [CI], 11.3 to 20.5) in the inavolisib group and 7.3 months (95% CI, 5.6 to 9.3) in the placebo group (hazard ratio for disease progression or death, 0.43; 95% CI, 0.32 to 0.59; P<0.001). An objective response occurred in 58.4% of the patients in the inavolisib group and in 25.0% of those in the placebo group. The incidence of grade 3 or 4 neutropenia was 80.2% in the inavolisib group and 78.4% in the placebo group; grade 3 or 4 hyperglycemia, 5.6% and 0%, respectively; grade 3 or 4 stomatitis or mucosal inflammation, 5.6% and 0%; and grade 3 or 4 diarrhea, 3.7% and 0%. No grade 3 or 4 rash was observed. Discontinuation of any trial agent because of adverse events occurred in 6.8% of the patients in the inavolisib group and in 0.6% of those in the placebo group.</p><p><strong>Conclusions: </strong>In patients with <i>PIK3CA</i>-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, inavolisib plus palbociclib-fulvestrant led to significantly longer progression-free survival than placebo plus palbociclib-fulvestrant, with a greater incidence of toxic effects. The percentage of patients who discontinued any trial agent because of adverse events was low. (Funded by F. Hoffmann-La Roche; INAVO120 ClinicalTrials.gov number, NCT04191499.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postacute Sequelae of SARS-CoV-2 Infection in Several Eras. Reply. 几个时代 SARS-CoV-2 感染的急性后遗症。回复。
IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-31 DOI: 10.1056/NEJMc2411213
Yan Xie, Ziyad Al-Aly
{"title":"Postacute Sequelae of SARS-CoV-2 Infection in Several Eras. Reply.","authors":"Yan Xie, Ziyad Al-Aly","doi":"10.1056/NEJMc2411213","DOIUrl":"10.1056/NEJMc2411213","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
New England Journal of Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1